Who are BioCart™II's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hylan GF-20 alone, Hyaluronic Acid Injection, Hyaluronic acid (HA), viscosupplementation 1+1+1, injection of hyaluronic acid., Hyalgan (sodium hyaluronate).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biocartii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BioCart™II — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BioCart™II (BioCart™II) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viscosupplement. Area: Rheumatology.

phase 2 Viscosupplement Rheumatology Biologic Live · refreshed every 30 min

Target snapshot

BioCart™II (BioCart™II) — ProChon Biotech Ltd. BioCart II is a hyaluronic acid-based viscosupplement used to treat joint pain and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BioCart™II TARGET	BioCart™II	ProChon Biotech Ltd	phase 2	Viscosupplement
Hylan GF-20 alone	Hylan GF-20 alone	University of Sao Paulo General Hospital	marketed	Viscosupplement	Hyaluronic acid receptor (CD44)
Hyaluronic Acid Injection	Hyaluronic Acid Injection	Wroclaw Medical University	marketed	Viscosupplement
Hyaluronic acid (HA)	Hyaluronic acid (HA)	Chinese University of Hong Kong	marketed	Viscosupplement / Biological polymer
viscosupplementation 1+1+1	viscosupplementation 1+1+1	University of Sao Paulo General Hospital	marketed	Hyaluronic acid derivative; viscosupplement	Hyaluronic acid receptor (CD44); joint synovial fluid
injection of hyaluronic acid.	injection of hyaluronic acid.	Istituto Ortopedico Rizzoli	marketed	Viscosupplement	Joint synovial fluid (viscoelastic properties)
Hyalgan (sodium hyaluronate)	Hyalgan (sodium hyaluronate)	Sanofi	marketed	Viscosupplement	Synovial fluid replacement (non-receptor mediated)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viscosupplement class)

Istituto Ortopedico Rizzoli · 1 drug in this class
LG Life Sciences · 1 drug in this class
ProChon Biotech Ltd · 1 drug in this class
Sanofi · 1 drug in this class
Taipei Medical University · 1 drug in this class
University of Sao Paulo General Hospital · 1 drug in this class
Wroclaw Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BioCart™II — Competitive Intelligence Brief. https://druglandscape.com/ci/biocartii. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing